Full-Time

Post Market Surveillance Adverse Event Analyst

Surgery Nurse / Nursing Background preferred

Posted on 11/1/2025

Intuitive Surgical

Intuitive Surgical

10,001+ employees

Manufactures robotic surgical systems and services

No salary listed

Norcross, GA, USA

In Person

Category
Medical, Clinical & Veterinary (5)
, , , ,
Requirements
  • Minimum Undergraduate degree, preferably in life science (e.g., RN, engineering), or undergraduate degree with post-market surveillance experience.
  • Minimum 3+ years of experience in medical device field, with experience in the following areas:
  • Working knowledge and understanding of the FDA 21 CFR part 803 Medical Device Reporting and part 820.198 for Complaint File management
  • Global regulatory medical device requirements for EU, MDSAP countries, and other related requirements
  • Effectively prioritize / multi-task numerous activities in a rapid paced environment
  • Demonstrate exceptional written and verbal communication skills
  • Effective computer skills (Excel, Word, PowerPoint, database query)
  • Efficient at autonomously working with ability to focus
  • Attention to detail
  • Demonstrate cross functional communication skills in email and in person
  • Demonstrate customer service based phone communication skills / obtain event details live from varied disciplines (hospital personnel, Intuitive representatives) in a professional manner
  • Proven analytical and Excellent organizational skills
  • Ability to handle and manage workload autonomously
  • Contribute to team-oriented tasks
  • Excellent interpersonal and decision-making skills
  • Firm understanding of Regulatory reporting requirements for Medical Devices and complaint system and process requirements including good documentation practices and quality system elements.
  • Firm understanding of quality records requirements and how they apply to complaint files.
  • Familiarity with world-wide regulatory reporting requirements.
  • Able to make decisions quickly using information at hand and evaluate the need to obtain clarification and direction when necessary.
Responsibilities
  • Investigating serious injury / adverse event and death complaints daily
  • Perform the preliminary classification of complaints including reportability triage and decision making
  • Conduct complaint investigations including following up with surgeons and other health care professionals via phone and email
  • Answer live, incoming phone calls for Adverse Events from Customer Service, Technical Service, Intuitive Representatives and hospital site contacts (e.g., surgeons, physicians, operating room personnel). Collect in-depth information as available, and document complaint into the CRM system
  • Perform reportability determinations in conjunction with medical safety officer, as necessary
  • Provide input to clinical conclusion to be included in the complaint file and regulatory reports
  • Escalate complaints that require additional review to engineering, medical safety officer, clinical development engineering, etc.
  • Accurately select Risk (Hazard, Harms, Severity, matching Clinical Risk Assessment line item) and IMDRF codes
  • Review product analysis investigation and determine cause / contribution of event to device
  • Draft and file medical device and vigilance Reports
  • Evaluate documentation for completeness and consistency
  • Approve final complaint file for closure after all applicable actions are completed
  • Manage complaint workload to required timeliness and goals
  • Collaborate with internal teams including clinical development engineering, human factors, medical safety office, risk management, engineering, and other departments as needed to provide relevant and critical clinical information related to adverse events
  • Adherence to standard operating procedures and guidance documents across the organization for reporting, investigation and compliance related to post market requirements
  • Analyze complaint data to identify trends, issues, or systemic discrepancies
  • Recognize and escalate trends and alert limits or process triggers of safety concerns to defined escalation path to communicate these concerns
  • Provide the risk management team required data to support and incorporate new failure modes into risk management files
  • Collaborate with the Medical Safety Office to support monitoring activities and ensure timely escalations.
  • Collaborate with the Intuitive Legal Department for legal claims
  • Ensure compliance to post market surveillance processes for regulatory database searches, literature reviews, surveys, and other proactive surveillance
  • Assess product relationship to reported complaints to root cause
  • Align to standard regulatory reporting assessment criteria
  • Collaborate on responses for Regulatory Agency Requests for additional information as assigned
  • Represent Post Market Surveillance at selected cross functional meetings
  • Provide monthly, daily, weekly reporting of key metrics and action plans
  • Drive the progress of complaints throughout the complaint lifecycle to ensure proper documentation and timely closure of each complaint
  • Participate in internal and external audits
  • Develop and maintain product knowledge of existing and new products
  • Maintain awareness of new or revised regulations and/or guidelines
  • Provide peer review and feedback of complaints and reports
  • Participate in new hire training and continuous Regulatory Compliance training as required
  • Participate in process improvement activities to continuously improve process effectiveness
  • Execute on projects as required
  • Perform other duties as directed
Desired Qualifications
  • Operating Room, Surgical, Critical Care experience preferred.

Intuitive Surgical designs, manufactures, and sells robotic surgical systems and provides related services and accessories for minimally invasive surgery. The core product helps surgeons perform operations with enhanced precision by guiding robotic arms controlled from a console, allowing procedures to be done through small incisions. Instruments and consumables are used with the systems and are supported by service contracts, creating a recurring revenue stream. Compared to competitors, Intuitive has a large installed base and focuses specifically on robotic-assisted surgery, combining devices, disposable instruments, and ongoing services to support hospitals and surgical centers. Its goal is to improve patient outcomes by enabling safer, less invasive procedures while expanding the use and capabilities of robotic surgery for more procedures and providers.

Company Size

10,001+

Company Stage

IPO

Headquarters

Sunnyvale, California

Founded

1995

Simplify Jobs

Simplify's Take

What believers are saying

  • Bariatric surgery market expansion as da Vinci outperforms GLP-1 drugs for sustained weight loss.
  • Ion bronchoscopy system procedures grew 39% YoY with 1,041 installed units capturing lung cancer detection.
  • Less than 5% of eligible surgeries globally performed robotically indicates substantial international adoption runway.

What critics are saying

  • FDA Class II recalls of instruments with fraying cables disrupt 86% of Q1 recurring revenue.
  • FDA safety communication on curved tip staplers halts hospital use, eroding surgeon confidence in reliability.
  • EU MDR recertification deadline December 2028 halts 25% European sales during redesign and testing.

What makes Intuitive Surgical unique

  • 70-80% market share in soft-tissue robotics with 11,395 installed da Vinci systems globally.
  • 85% recurring revenue from instruments, accessories, and service contracts provides predictable cash flow.
  • da Vinci 5 platform expands into cardiac surgery and complex procedures previously requiring open surgery.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Apr 7th, 2026
Intuitive Surgical emerges as dark horse in anti-obesity market as surgery outperforms GLP-1 drugs

Intuitive Surgical could emerge as a dark horse in the anti-obesity market as bariatric surgery proves more effective than GLP-1 drugs for long-term weight loss. A recent study of over 50,000 patients found surgery patients lost an average of 58 pounds after two years, compared to just 12 pounds for those using GLP-1 medications. The study also showed surgery delivers more sustainable results. Gastric bypass patients maintain around 52% of their excess weight loss after 10 years, whilst GLP-1 users often regain all lost weight after stopping treatment. Intuitive's da Vinci surgical system offers minimally invasive bariatric surgery options. The company generated $10.1 billion in revenue last year, up from $8.4 billion, with profit margins around 28%. Despite shares falling over 20% this year, the company's position in surgical innovation makes it a compelling long-term investment.

Yahoo Finance
Mar 29th, 2026
Intuitive Surgical shares drop 19% YTD, but analysts see 15% upside potential

Intuitive Surgical has experienced recent share price weakness, declining 3% in one day with negative returns over the past week, month and three months. The stock currently trades at $452.66, down 10.1% over one month and 19.45% year-to-date, though three-year total shareholder returns remain strong at 77.19%. The medical technology company reports annual revenue of $10.1 billion and net income of $2.9 billion, maintaining a dominant position in minimally invasive surgical technology. According to one valuation analysis, Intuitive Surgical's fair value sits at $532.46, suggesting the stock is undervalued by approximately 15% at current levels. The analysis projects 12% annual revenue growth over the next five years, supported by recurring revenues from spare parts and software licences, with profit margins expected to reach 30% from the current 28.6%.

Yahoo Finance
Mar 28th, 2026
Intuitive Surgical shares up 23% after Jim Cramer's buy recommendation

Intuitive Surgical shares rose 23% following Jim Cramer's recommendation on CNBC's Squawk on the Street in June 2025, where he urged investors to "just go buy ISRG". The medical robotics company experienced a 27% surge in October after reporting third-quarter earnings that beat analyst estimates. Revenue reached $2.51 billion against expectations of $2.40 billion, whilst adjusted earnings per share hit $2.40 versus the predicted $1.98. However, the stock declined 2.7% in January 2026 after Intuitive Surgical released preliminary fourth-quarter results, citing concerns that Medicaid funding cuts and competing products could slow growth of its robotic surgical systems. Despite the recent setback, shares remain up significantly since Cramer's initial endorsement, though they're down 7.8% over the past year.

Yahoo Finance
Mar 28th, 2026
Intuitive Surgical faces tariff headwinds and rising competition despite 19% revenue growth to $2.87B

Intuitive Surgical faces headwinds from tariffs and increased competition in the robotic-assisted surgery market, yet its fundamentals remain strong. The medical device company reported fourth-quarter revenue growth of 19% to $2.87 billion, whilst adjusted earnings per share rose 14.5% to $2.53. Procedures using its da Vinci surgical system increased 17%, with the installed base growing 12% to 11,106 units. However, the stock trades at 47.6 times forward earnings, compared to the healthcare sector average of 17.1. New competition is emerging, with Medtronic's Hugo system recently cleared and Johnson & Johnson expected to launch its own device soon. Despite these challenges, Intuitive Surgical maintains advantages through switching costs and extensive real-world data, whilst the underpenetrated robotic-assisted surgery market offers long-term growth potential.

Yahoo Finance
Mar 24th, 2026
ISRG maintains 37% operating margins in Q4 despite 95 bps tariff drag

Intuitive Surgical maintained a 37% operating margin in Q4 despite tariffs creating a 95 basis point drag, alongside higher facility costs and unfavourable product mix from newer platforms like da Vinci 5 and Ion. The company offset these pressures through product cost reductions, component savings and manufacturing efficiencies. Procedure growth of 18% in Q4 and recurring revenue now comprising 81% of total revenues provided operating leverage. Management's 2026 gross margin guidance of 67-68% suggests continued stability, even as tariff headwinds are expected to increase to roughly 1.2% of revenues. Meanwhile, Boston Scientific expanded adjusted operating margins by 100 basis points to 28% in 2025, though tariffs will offset favourable product mix in 2026. The company expects 50-75 basis points operating margin expansion in 2026 through scale efficiencies and supply-chain optimisation.

INACTIVE